1. Home
  2. BNGO vs INAB Comparison

BNGO vs INAB Comparison

Compare BNGO & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bionano Genomics Inc.

BNGO

Bionano Genomics Inc.

HOLD

Current Price

$1.15

Market Cap

12.5M

Sector

Industrials

ML Signal

HOLD

Logo IN8bio Inc.

INAB

IN8bio Inc.

HOLD

Current Price

$0.97

Market Cap

11.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BNGO
INAB
Founded
2003
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Laboratory Analytical Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.5M
11.8M
IPO Year
2018
2020

Fundamental Metrics

Financial Performance
Metric
BNGO
INAB
Price
$1.15
$0.97
Analyst Decision
Buy
Strong Buy
Analyst Count
2
3
Target Price
$5.00
★ $7.00
AVG Volume (30 Days)
★ 271.9K
36.7K
Earning Date
11-12-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 94.50
N/A
EPS
N/A
★ N/A
Revenue
★ $12,000,735.00
N/A
Revenue This Year
$12.73
N/A
Revenue Next Year
$34.74
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 26.26
N/A
52 Week Low
$1.00
$0.88
52 Week High
$2.23
$2.73

Technical Indicators

Market Signals
Indicator
BNGO
INAB
Relative Strength Index (RSI) 32.20 35.57
Support Level $1.10 $0.92
Resistance Level $1.19 $1.22
Average True Range (ATR) 0.08 0.09
MACD -0.03 -0.04
Stochastic Oscillator 13.75 20.33

Price Performance

Historical Comparison
BNGO
INAB

About BNGO Bionano Genomics Inc.

Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.

About INAB IN8bio Inc.

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.

Share on Social Networks: